EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do

Saverio D'Elia iD, Mariarosaria Morello iD, Gisella Titolo, Valentina Maria Caso, Achille Solimene, Ettore Luisi, Chiara Serpico, Andrea Morello, Lucia La Mura iD, Francesco S Loffredo, Francesco Natale iD, Paolo Golino iD und 1 weitere

Journal of Cardiovascular Development and Disease · 27.09.2025 · 12 (10) · 383

DOI: 10.3390/jcdd12100383 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 27.09.2025. Verfasst von Saverio D'Elia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Naples, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Homocysteine has long been studied as a potential cardiovascular risk factor due to its biochemical role in endothelial dysfunction, oxidative stress, inflammation, and thrombogenesis. Despite strong epidemiological and mechanistic support, the translation of homocysteine-lowering interventions into clinical benefit remains controversial. This non-systematic review aims to clarify the current understanding of homocysteine in the cardiovascular setting by distinguishing between well-established facts, clinically relevant interventions, and persistent misconceptions. We first revisit the historical emergence of homocysteine as a cardiovascular biomarker and explore its pathophysiological mechanisms, including endothelial damage, atherosclerosis progression, and prothrombotic effects—supported by in vitro and animal model studies. Subsequently, we evaluate evidence-based interventions such as B-vitamin supplementation (folate, B6, B12), lifestyle modifications, and the clinical relevance of homocysteine monitoring in specific populations (e.g., MTHFR mutations, chronic kidney disease). We then discuss common pitfalls, including the overinterpretation of genetic variants, the inappropriate use of supplementation, and the overreliance on surrogate biomarkers in clinical trials. Although elevated homocysteine remains a reproducible biomarker of cardiovascular risk, current evidence does not support routine intervention in unselected populations. A precision medicine approach—targeting high-risk subgroups and integrating homocysteine into broader cardiometabolic management—may help unlock its therapeutic relevance. Future pharmacological strategies should prioritize mechanistic insight, patient stratification, and clinically meaningful endpoints.

Schlagwörter

Stichwörter der Autor:innen

B vitaminsMTHFRcardiovascular riskendothelial dysfunctionfolatehomocysteinenutraceuticalsprecision medicine

Autor:innen und Institutionen

  • Cardiology Unit, Azienda Ospedaliera Universitaria Luigi Vanvitelli, 80138 Naples, Italy.
  • Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, Piazza Luigi Miraglia, 2, 80138 Naples, Italy.
  • Department of Translational Medical Sciences, Section of Cardiology, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.
  • Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
  • Pharmacy Unit, Monaldi Hospital, 80131 Naples, Italy.
  • Laboratory Medicine Unit, Azienda Sanitaria Regionale Molise, Antonio Cardarelli Hospital, 86100 Campobasso, Italy.

ORCID-Profile: Saverio D'Elia, Mariarosaria Morello, Lucia La Mura, Francesco Natale, Paolo Golino, Giovanni Cimmino

Zitieren

APA

D'Elia, S., Morello, M., Titolo, G., Caso, V. M., Solimene, A., Luisi, E., Serpico, C., Morello, A., La Mura, L., Loffredo, F. S., Natale, F., Golino, P., & Cimmino, G. (2025). Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do. Journal of Cardiovascular Development and Disease, 12(10), 383. https://doi.org/10.3390/jcdd12100383

Vancouver

D'Elia S, Morello M, Titolo G, Caso VM, Solimene A, Luisi E, et al. Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do. Journal of Cardiovascular Development and Disease. 2025;12(10):383. doi:10.3390/jcdd12100383

BibTeX
@article{DElia2025,
  author = {D'Elia, Saverio and Morello, Mariarosaria and Titolo, Gisella and Caso, Valentina Maria and Solimene, Achille and Luisi, Ettore and Serpico, Chiara and Morello, Andrea and La Mura, Lucia and Loffredo, Francesco S and Natale, Francesco and Golino, Paolo and Cimmino, Giovanni},
  title = {Homocysteine in the Cardiovascular Setting: What to Know, What to Do, and What Not to Do},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2025},
  volume = {12},
  number = {10},
  pages = {383},
  doi = {10.3390/jcdd12100383}
}
Kostenlos starten →